ALNY : Analysis & Opinions

  1. Bull of the Day: Alexion Pharma (ALXN) - Bull of the Day

    February 24, 2014
    Bull of the Day: Alexion Pharma (ALXN) - Bull of the Day
  2. Peregrine's 4Q Loss In Line - Analyst Blog

    July 15, 2013
    Peregrine Pharma reported a net loss of 6 cents per share in the fourth quarter of fiscal 2013.
  3. Alnylam Up to Positive Data - Analyst Blog

    July 12, 2013
    Alnylam announced positive top-line results from a phase I study on ALN-TTRsc.
  4. Northera NDA Resubmitted By Chelsea - Analyst Blog

    July 11, 2013
    Chelsea Therapeutics resubmitted a new drug application for Northera.
  5. Australian Approval for Vertex' Kalydeco - Analyst Blog

    July 10, 2013
    Kalydeco sales should benefit from reimbursement in additional European countries and launch in new markets.
  6. Celgene Inks Oncology Deal - Analyst Blog

    June 27, 2013
    Celgene has joined forces with MorphoSys.
  7. Celgene presents Revlimid Data - Analyst Blog

    June 26, 2013
    Celgene presented data on in patients suffering from various forms of non-Hodgkin's lymphoma
  8. Gilead Retained at Neutral - Analyst Blog

    June 25, 2013
    We recently maintained our Neutral recommendation on , Gilead Sciences.
  9. Alnylam-MDCO Join for ALN-PCS - Analyst Blog

    February 5, 2013
    Alnylam Pharmaceuticals Inc. (ALNY) recently entered into an exclusive global alliance with The Medicines Company (MDCO) ...
  10. Alnylam Prices Public Offering - Analyst Blog

    January 16, 2013
    Alnylam Pharmaceuticals Inc. (ALNY) provided pricing and other details regarding its recently announced public offering of ...
  11. Eli Lilly and Other Healthcare Stocks Making Big Moves on December ...

    December 12, 2012
    The Nasdaq remains relatively unchanged, the S&P 500 has moved up 0.2% and the Dow is up 0.2% after the morning's trading. ...
  12. Isis Pharma Owns 18% of Regulus - Analyst Blog

    October 12, 2012
    Isis Pharmaceuticals, Inc. (ISIS) recently announced that it has invested $3 million in biopharma company Regulus Therapeutics ...
  13. Alnylam-ISIS Venture Prices IPO - Analyst Blog

    October 5, 2012
    Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals, Inc. (ISIS), recently announced ...
  14. Healthcare Stocks, Including Taro Pharmaceutical, Making Big ...

    September 19, 2012
    On a good day for the market, the Nasdaq has increased 0.1%, the S&P 500 is trading up 0.2% and the Dow is up 0.3%. The healthcare ...
  15. Pharmacyclics Among Healthcare's Biggest Movers on August 28, ...

    August 28, 2012
    On a bad day for the market, the Nasdaq has slipped 0.1%, the S&P 500 is trading down 0.1% and the Dow has decreased 0.1%. ...
  16. Alnylam/Isis's Regulus to Go Public - Analyst Blog

    August 22, 2012
    Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals, Inc. (ISIS), recently announced ...
  17. Biogen Inks Deal with Regulus - Analyst Blog

    August 16, 2012
    Regulus Therapeutics Inc. and Biogen Idec (BIIB) recently entered into a deal to identify microRNAs (micro-RiboNucleic Acids) ...
  18. Big Movers on the Healthcare Sector Today, Including VRX

    August 7, 2012
    The market is having a good day so far: the Nasdaq has climbed 0.8%; the S&P 500 is up 0.7%; and the Dow has risen 0.6%. ...
  19. Alnylam Earns Milestone Payment - Analyst Blog

    August 6, 2012
    Alnylam Pharmaceuticals Inc. (ALNY) recently earned development milestone payment of $3.2 million from GlaxoSmithKline (GSK). ...
  20. Healthcare Sector's Biggest Movers for July 17, 2012

    July 17, 2012
    The Nasdaq has slipped 0.1%, the S&P 500 has declined 0.1% and the Dow is trading down 0.2% on a bad morning for the market. ...
  21. Healthcare Stocks Making Big Moves on July 16, 2012

    July 16, 2012
    After the morning's trading, the Nasdaq has been relatively flat, the S&P 500 has fallen 0.1% and the Dow has slipped 0.3%. ...
  22. Good IPO, Bad IPO

    June 17, 2009
    A good IPO will consider the needs of long-time investors as well as new ones. Here is the good the bad about two IPOs.
Investing News
  1. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  2. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  3. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  4. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  5. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
  6. Can Paying Off Your Mortgage Early Hurt Your Net Worth?

    Saving your money and making double or even triple payments on a mortgage may sound productive, ...
Trading Center